Drug Trial Radar · NCT03117751
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
790
Actual
Start
Mar 29, 2017
Primary completion
Sep 30, 2026
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Incyte Corporation; Amgen; Servier
- First posted
- Apr 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Primary Therapeutic Objectives: * To improve the event-free survival of provisional standard- or high-risk patients with genetically or immunologically targetable lesions or minimal residual disease (MRD) ≥ 5% at Day 15 or Day 22 or ≥1% at the end of Remission Induction, by the addition of molecular and immunotherapeutic approaches including tyrosine kinase inhibitors or chimeric antigen receptor (CAR) T cell / blinatumomab for refractory B-acute lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), and the proteasome inhibitor bortezomib for those lacking targetable lesions. * To improve overall treatment outcome of T acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy) by optimizing pegaspargase and cyclophosphamide treatment and by the addition of new agents in patients with targetable genomic abnormalities (e.g., activated tyrosine kinases or JAK/STAT mutations) or by the addition of bortezomib for those who have a poor early response to treatment but no targetable lesions, and by administering nelarabine to T-ALL and T-LLy patients with leukemia/lymphoma cells in cerebrospinal fluid at diagnosis or MRD ≥0.01% at the end of induction. * To determine in a randomized study design whether the incidence and/or severity of acute vincristine-induced peripheral neuropathy can be reduced by decreasing the dosage of vincristine in patients with the high-risk CEP72 TT genotype or by shortening the duration of vincristine therapy in standard/high-risk patients with the CEP72 CC or CT genotype. Secondary Therapeutic Objectives: * To estimate the event-free survival and overall survival of children with ALL and to assess the non-inferiority of TOTXVII compared to the historical control given by TOTXVI. * To estimate the event-free survival and overall survival of children with LLy when ALL diagnostic and treatment approaches are used. * To evaluate the efficacy of blinatumomab in B-ALL patients with end of induction MRD ≥0.01% to \<1% and those (regardless of MRD level or TOTXVII risk category) with the genetic subtypes of BCR-ABL1, ABL-class fusion, JAK-STAT activating mutation, hypodiploid, iAMP21, ETV6-RUNX1-like, MEF2D, TCF3-HLF, or BCL2/MYC or with Down syndrome, by comparing event-free survival to historical control from TOTXVI. * To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. Biological Objectives: * To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. * To evaluate and implement deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing-based methods to monitor levels of MRD in bone marrow, blood, and cerebrospinal fluid. * To assess clonal diversity and evolution of pre-leukemic and leukemic populations using DNA variant detection and single-cell genomic analyses in a non-clinical, research setting. * To identify germline or somatic genomic variants associated with drug resistance of ALL cells to conventional and newer targeted anti-leukemic agents in a non-clinical, research setting. * To compare drug sensitivity of ALL cells from diagnosis to relapse in vitro and in vivo and determine if acquired resistance to specific agents is related to specific somatic genome variants that are not detected or found in only a minor clone at initial diagnosis. Supportive Care Objectives * To conduct serial neurocognitive monitoring of patients to investigate the neurocognitive trajectory, mechanisms, and risk factors. * To evaluate the impact of low-magnitude high frequency mechanical stimulation on bone mineral density and markers of bone turnover. There are several Exploratory Objectives.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Lymphoma
Interventions
PrednisoneDrug
Given orally (PO).
VincristineDrug
Given intravenously (IV).
DaunorubicinDrug
Given IV.
PegaspargaseDrug
Given IV or intramuscularly (IM) .
Erwinase®Drug
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
CyclophosphamideDrug
Given IV.
CytarabineDrug
Given IV or by subcutaneous injection (SQ).
MercaptopurineDrug
Given PO.
DasatinibDrug
Given PO.
MethotrexateDrug
Given IV.
BlinatumomabDrug
Given IV.
RuxolitinibDrug
Given PO.
BortezomibDrug
Given IV or subcutaneously (SQ).
DexamethasoneDrug
Given PO.
DoxorubicinDrug
Given IV.
EtoposideDrug
Given IV.
ClofarabineDrug
Given IV.
VorinostatDrug
Given PO.
IdarubicinDrug
Given IV.
NelarabineDrug
Given IV.
ThioguanineDrug
Participants with mercaptopurine-related pancreatitis. Given PO.
Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
Calaspargase PegolDrug
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival of ALL patients (EFS)Time frame: At 3.5 years after enrollment of the last participant
- Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during ContinuationTime frame: At 6 months after the last randomized patient completes Continuation Treatment (Week 120).
- Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotypeTime frame: After the last randomized patient is followed for 1 year after Week 101 of Continuation therapy
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
Rady Children's Hospital San Diego
San Diego, California
Children's Hospital of Illinois at OSF-Saint Francis Medical Center (St. Jude Midwest Affiliate - Peoria)
Peoria, Illinois
Children's Hospital of Michigan
Detroit, Michigan
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital
Charlotte, North Carolina
St. Jude Children's Research Hospital
Memphis, Tennessee
Cook Children's Medical Center
Fort Worth, Texas
The Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.